These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Effectiveness of mRNA-1273 and BNT162b2 Vaccines in Qatar. Abu-Raddad LJ; Chemaitelly H; Bertollini R; N Engl J Med; 2022 Feb; 386(8):799-800. PubMed ID: 35045222 [No Abstract] [Full Text] [Related]
3. Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar. Chemaitelly H; Tang P; Hasan MR; AlMukdad S; Yassine HM; Benslimane FM; Al Khatib HA; Coyle P; Ayoub HH; Al Kanaani Z; Al Kuwari E; Jeremijenko A; Kaleeckal AH; Latif AN; Shaik RM; Abdul Rahim HF; Nasrallah GK; Al Kuwari MG; Al Romaihi HE; Butt AA; Al-Thani MH; Al Khal A; Bertollini R; Abu-Raddad LJ N Engl J Med; 2021 Dec; 385(24):e83. PubMed ID: 34614327 [TBL] [Abstract][Full Text] [Related]
4. BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar. Tang P; Hasan MR; Chemaitelly H; Yassine HM; Benslimane FM; Al Khatib HA; AlMukdad S; Coyle P; Ayoub HH; Al Kanaani Z; Al Kuwari E; Jeremijenko A; Kaleeckal AH; Latif AN; Shaik RM; Abdul Rahim HF; Nasrallah GK; Al Kuwari MG; Al Romaihi HE; Butt AA; Al-Thani MH; Al Khal A; Bertollini R; Abu-Raddad LJ Nat Med; 2021 Dec; 27(12):2136-2143. PubMed ID: 34728831 [TBL] [Abstract][Full Text] [Related]
5. Effectiveness of mRNA vaccines and waning of protection against SARS-CoV-2 infection and severe covid-19 during predominant circulation of the delta variant in Italy: retrospective cohort study. Fabiani M; Puopolo M; Morciano C; Spuri M; Spila Alegiani S; Filia A; D'Ancona F; Del Manso M; Riccardo F; Tallon M; Proietti V; Sacco C; Massari M; Da Cas R; Mateo-Urdiales A; Siddu A; Battilomo S; Bella A; Palamara AT; Popoli P; Brusaferro S; Rezza G; Menniti Ippolito F; Pezzotti P; BMJ; 2022 Feb; 376():e069052. PubMed ID: 35144968 [TBL] [Abstract][Full Text] [Related]
7. Audio Interview: Waning Immunity against SARS-CoV-2. Rubin EJ; Baden LR; Morrissey S N Engl J Med; 2021 Dec; 385(24):e99. PubMed ID: 34879456 [No Abstract] [Full Text] [Related]
8. Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccine-boosted nonhuman primates. Corbett KS; Gagne M; Wagner DA; O' Connell S; Narpala SR; Flebbe DR; Andrew SF; Davis RL; Flynn B; Johnston TS; Stringham CD; Lai L; Valentin D; Van Ry A; Flinchbaugh Z; Werner AP; Moliva JI; Sriparna M; O'Dell S; Schmidt SD; Tucker C; Choi A; Koch M; Bock KW; Minai M; Nagata BM; Alvarado GS; Henry AR; Laboune F; Schramm CA; Zhang Y; Yang ES; Wang L; Choe M; Boyoglu-Barnum S; Wei S; Lamb E; Nurmukhambetova ST; Provost SJ; Donaldson MM; Marquez J; Todd JM; Cook A; Dodson A; Pekosz A; Boritz E; Ploquin A; Doria-Rose N; Pessaint L; Andersen H; Foulds KE; Misasi J; Wu K; Carfi A; Nason MC; Mascola J; Moore IN; Edwards DK; Lewis MG; Suthar MS; Roederer M; McDermott A; Douek DC; Sullivan NJ; Graham BS; Seder RA Science; 2021 Dec; 374(6573):1343-1353. PubMed ID: 34672695 [TBL] [Abstract][Full Text] [Related]
9. Standardised neutralising antibody assays are needed for evaluating COVID-19 vaccines. Wang Y EBioMedicine; 2021 Nov; 73():103677. PubMed ID: 34742128 [No Abstract] [Full Text] [Related]
10. Comparative Effectiveness and Antibody Responses to Moderna and Pfizer-BioNTech COVID-19 Vaccines among Hospitalized Veterans - Five Veterans Affairs Medical Centers, United States, February 1-September 30, 2021. Bajema KL; Dahl RM; Evener SL; Prill MM; Rodriguez-Barradas MC; Marconi VC; Beenhouwer DO; Holodniy M; Lucero-Obusan C; Brown ST; Tremarelli M; Epperson M; Mills L; Park SH; Rivera-Dominguez G; Morones RG; Ahmadi-Izadi G; Deovic R; Mendoza C; Jeong C; Schrag SJ; Meites E; Hall AJ; Kobayashi M; McMorrow M; Verani JR; Thornburg NJ; Surie D; ; ; MMWR Morb Mortal Wkly Rep; 2021 Dec; 70(49):1700-1705. PubMed ID: 34882654 [TBL] [Abstract][Full Text] [Related]
11. mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. Chemaitelly H; Yassine HM; Benslimane FM; Al Khatib HA; Tang P; Hasan MR; Malek JA; Coyle P; Ayoub HH; Al Kanaani Z; Al Kuwari E; Jeremijenko A; Kaleeckal AH; Latif AN; Shaik RM; Abdul Rahim HF; Nasrallah GK; Al Kuwari MG; Al Romaihi HE; Al-Thani MH; Al Khal A; Butt AA; Bertollini R; Abu-Raddad LJ Nat Med; 2021 Sep; 27(9):1614-1621. PubMed ID: 34244681 [TBL] [Abstract][Full Text] [Related]
12. Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants. Abu-Raddad LJ; Chemaitelly H; Butt AA; N Engl J Med; 2021 Jul; 385(2):187-189. PubMed ID: 33951357 [No Abstract] [Full Text] [Related]
13. Homing In On a SARS-CoV-2 Correlate of Protection. Abbasi J JAMA; 2022 Jan; 327(2):115. PubMed ID: 35015053 [No Abstract] [Full Text] [Related]
14. Effectiveness of COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe outcomes with variants of concern in Ontario. Nasreen S; Chung H; He S; Brown KA; Gubbay JB; Buchan SA; Fell DB; Austin PC; Schwartz KL; Sundaram ME; Calzavara A; Chen B; Tadrous M; Wilson K; Wilson SE; Kwong JC; Nat Microbiol; 2022 Mar; 7(3):379-385. PubMed ID: 35132198 [TBL] [Abstract][Full Text] [Related]
15. Incidence and Estimated Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Among Persons Tested in US Retail Locations, May 1 to August 7, 2021. Tabak YP; Sun X; Brennan TA; Chaguturu SK JAMA Netw Open; 2021 Dec; 4(12):e2143346. PubMed ID: 34935923 [TBL] [Abstract][Full Text] [Related]